Our Company
Xanamem^® (emestedastat)
Clinical Trials
Investor Centre
News
Contact Us

BACK TO NEWS

admin • 12 Jan 2023

Spark Plus Research Note
Actinogen – A company to never forget

Enjoyed this read?

Stay up to date with our latest research.

Related articles

Press Releases and Media

Daily pill to treat dementia gets nod

Courier Mail • September 17, 2025

Press Releases and Media

A novel oral treatment for Alzheimer’s: Actinogen’s pivotal trial currently recruiting participants in the US

PR Newswire • July 22, 2025

Press Releases and Media

FIVEAA Adelaide radio interview with Dr Steven Gourlay on once-a-day Alzheimer’s pill [8m 25s]

FIVEAA • July 1, 2025

Our Company
Xanamem^® (emestedastat)

Clinical Trials

Investors
News
Contact Us
Target Market Determination

Copyright © 2026 Actinogen